Published in J Pharm Sci on February 01, 2006
Classification and characterization of therapeutic antibody aggregates. J Biol Chem (2011) 1.28
Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci (2008) 1.21
Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol (2013) 1.10
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem (2012) 1.09
Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS PharmSciTech (2008) 1.01
Modifications of therapeutic proteins: challenges and prospects. Cytotechnology (2007) 1.00
Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. J Phys Chem B (2009) 1.00
A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood (2009) 0.97
Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J (2010) 0.97
Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function. Clin Immunol (2010) 0.90
Protein particulate detection issues in biotherapeutics development--current status. AAPS PharmSciTech (2012) 0.88
Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J (2009) 0.84
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci (2012) 0.84
Effects of disulfide bond formation and protein helicity on the aggregation of activating transcription factor 5. Mol Pharm (2009) 0.81
Influence of the valine zipper region on the structure and aggregation of the basic leucine zipper (bZIP) domain of activating transcription factor 5 (ATF5). Mol Pharm (2012) 0.77
Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta (2007) 0.77
Reduction of the C191-C220 disulfide of α-chymotrypsinogen A reduces nucleation barriers for aggregation. Biophys Chem (2013) 0.76
Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization. Immunol Cell Biol (2016) 0.75
The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling. J Immunol Res (2015) 0.75
Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol (1997) 5.95
Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature (1984) 4.19
T cell-dependent B cell activation. Annu Rev Immunol (1993) 3.81
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet (1995) 3.74
Structure of human factor VIII. Nature (1984) 3.29
Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol (1997) 3.24
Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov (2002) 2.49
Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther (2002) 2.33
The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost (1995) 2.25
Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem (1988) 1.96
Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res (1997) 1.91
Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost (2002) 1.70
Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem (2005) 1.39
Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost (1999) 1.30
Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost (2004) 1.17
Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys (1988) 1.13
Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab (1980) 1.11
Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost (2001) 1.10
Environmental and genetic factors influencing inhibitor development. Semin Hematol (2004) 1.08
Formulation design of acidic fibroblast growth factor. Pharm Res (1993) 1.07
Factor VIII structure and function. Blood Rev (1989) 1.03
Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost (2002) 1.03
Factor VIII inhibitors. Adv Exp Med Biol (2001) 1.02
Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry (2001) 1.02
Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost (2000) 1.01
Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol (1997) 1.00
Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology (2004) 1.00
Antigen stability controls antigen presentation. J Biol Chem (2004) 0.99
Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem (2003) 0.97
Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J Pharm Sci (2005) 0.96
Protein conformation significantly influences immune responses to prion protein. J Immunol (2005) 0.95
Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol (2004) 0.93
Factor VIII immunogenicity. Haemophilia (1998) 0.92
Aggregation kinetics of recombinant human FVIII (rFVIII). J Pharm Sci (2005) 0.89
Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci (2002) 0.88
Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost (2002) 0.88
A comparison of the immunogenicity of the native and denatured forms of a protein. APMIS (1996) 0.87
The role of pharmacokinetics in the development of biotechnologically derived agents. Clin Pharmacokinet (1992) 0.87
Inhibitors in haemophilia: pathophysiology. Haemophilia (2004) 0.87
The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel) (2003) 0.86
Correlation of rFVIII inactivation with aggregation in solution. Pharm Res (2003) 0.85
Heat denaturation affects the ProDer p 1 IgE reactivity and downregulates the development of the specific allergic response. J Allergy Clin Immunol (2004) 0.83
Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. Vaccine (1995) 0.83
A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions. Thromb Haemost (2003) 0.81
The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products. Transfus Med Rev (1997) 0.78
Characterization of aggregates of recombinant human factor VIII by size-exclusion chromatography and immunoassay. Biotechnol Appl Biochem (1996) 0.77
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect Immun (2006) 2.24
Nanotechnology in vaccine delivery. Adv Drug Deliv Rev (2008) 1.91
Barriers to nonviral gene delivery. J Pharm Sci (2003) 1.77
Biophysical characterization of PEI/DNA complexes. J Pharm Sci (2003) 1.44
Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J Biol Chem (2006) 1.41
Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem (2005) 1.39
Silicone oil induced aggregation of proteins. J Pharm Sci (2005) 1.32
Preparation and characterization of translocator/chaperone complexes and their component proteins from Shigella flexneri. Biochemistry (2007) 1.32
Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles. J Pharm Sci (2005) 1.27
Polyanions and the proteome. Mol Cell Proteomics (2004) 1.24
Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J Pharm Sci (2003) 1.21
Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem (2005) 1.19
Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev (2011) 1.19
Thermal stability of vaccines. J Pharm Sci (2003) 1.17
Structural stability of adenovirus type 5. J Pharm Sci (2003) 1.17
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci (2010) 1.16
Structure-function analysis of invasion plasmid antigen C (IpaC) from Shigella flexneri. J Biol Chem (2002) 1.15
Physical characterization of MxiH and PrgI, the needle component of the type III secretion apparatus from Shigella and Salmonella. Protein Sci (2006) 1.11
Conformational stability and differential structural analysis of LcrV, PcrV, BipD, and SipD from type III secretion systems. Protein Sci (2007) 1.10
Properties of synthetic spider silk fibers based on Argiope aurantia MaSp2. Biomacromolecules (2008) 1.08
A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J Pharm Sci (2007) 1.06
Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci (2006) 1.04
Effect of metal cations on the conformation and inactivation of recombinant human factor VIII. J Pharm Sci (2004) 1.04
The complex inter-relationships between protein flexibility and stability. J Pharm Sci (2008) 1.02
The structure of DNA within cationic lipid/DNA complexes. Biophys J (2003) 1.01
Identification of properties important to protein aggregation using feature selection. BMC Bioinformatics (2013) 1.00
Spectroscopic and calorimetric analyses of invasion plasmid antigen D (IpaD) from Shigella flexneri reveal the presence of two structural domains. Biochemistry (2006) 1.00
Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci (2007) 1.00
Oligomeric states of the Shigella translocator protein IpaB provide structural insights into formation of the type III secretion translocon. Protein Sci (2013) 0.99
Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1. J Pharm Sci (2007) 0.99
Insulin containing polyethylenimine-dextran sulfate nanoparticles. Int J Pharm (2003) 0.99
Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci (2011) 0.98
Characterization of the interaction of single tryptophan containing mutants of IpaC from Shigella flexneri with phospholipid membranes. Biochemistry (2006) 0.98
A novel scoring function for discriminating hyperthermophilic and mesophilic proteins with application to predicting relative thermostability of protein mutants. BMC Bioinformatics (2010) 0.98
Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochim Biophys Acta (2003) 0.97
Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J Pharm Sci (2005) 0.96
Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci (2012) 0.96
Stability of the Clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach. Mol Pharm (2007) 0.95
High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability. AAPS J (2013) 0.94
Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci (2011) 0.94
A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine (2006) 0.93
Structural stability of vault particles. J Pharm Sci (2009) 0.93
Effects of pH and polyanions on the thermal stability of fibroblast growth factor 20. Mol Pharm (2007) 0.92
An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1. Protein Sci (2012) 0.92
Biophysical characterization of Chlamydia trachomatis CT584 supports its potential role as a type III secretion needle tip protein. Biochemistry (2009) 0.92
Using empirical phase diagrams to understand the role of intramolecular dynamics in immunoglobulin G stability. J Pharm Sci (2009) 0.92
Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella. Vaccine (2013) 0.91
Comparative kinetics of cofactor association and dissociation for the human and trypanosomal S-adenosylhomocysteine hydrolases. 1. Basic features of the association and dissociation processes. Biochemistry (2007) 0.91
Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci (2012) 0.90
Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombinant hookworm vaccine through biophysical and formulation studies. Hum Vaccin Immunother (2012) 0.90
Compositional effects of cationic lipid/DNA delivery systems on transgene expression in cell culture. J Pharm Sci (2004) 0.89
Solution behavior of IFN-beta-1a: an empirical phase diagram based approach. J Pharm Sci (2005) 0.89
Aggregation kinetics of recombinant human FVIII (rFVIII). J Pharm Sci (2005) 0.89
The structural organization of cationic lipid-DNA complexes. J Biol Chem (2002) 0.89
A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams. J Pharm Sci (2008) 0.89
A network-based analysis of polyanion-binding proteins utilizing human protein arrays. J Biol Chem (2007) 0.89
Investigation of protein conformational stability employing a multimodal spectrometer. Anal Chem (2011) 0.89
Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen. Hum Vaccin Immunother (2013) 0.88
N-terminus of IpaB provides a potential anchor to the Shigella type III secretion system tip complex protein IpaD. Biochemistry (2013) 0.88
An improved methodology for multidimensional high-throughput preformulation characterization of protein conformational stability. J Pharm Sci (2012) 0.88
Electrostatic changes in phosphorylase kinase induced by its obligatory allosteric activator Ca2+. Protein Sci (2007) 0.88
Evaluation of the physical stability of the EC5 domain of E-cadherin: effects of pH, temperature, ionic strength, and disulfide bonds. J Pharm Sci (2009) 0.88
Fluorescence properties of Laurdan in cochleate phases. Biochim Biophys Acta (2003) 0.88
Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J Pharm Sci (2014) 0.88
Effect of polyanions on the structure and stability of repifermin (keratinocyte growth factor-2). J Pharm Sci (2007) 0.87
Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. J Pharm Sci (2012) 0.87
Investigation of protein/carbohydrate interactions in the dried state. 1. Calorimetric studies. J Pharm Sci (2002) 0.87
Stabilization of measles virus for vaccine formulation. Hum Vaccin (2008) 0.87
Physical characterization of clostridium difficile toxins and toxoids: effect of the formaldehyde crosslinking on thermal stability. J Pharm Sci (2008) 0.87
Investigation of protein/carbohydrate interactions in the dried state. 2. Diffuse reflectance FTIR studies. Int J Pharm (2002) 0.86
Stability of lyophilized human growth hormone. Int J Pharm (2008) 0.86
pH sensitivity of type III secretion system tip proteins. Proteins (2008) 0.86
Physical stabilization of Norwalk virus-like particles. J Pharm Sci (2008) 0.86
Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry (2013) 0.86
Effect of pH and ionic strength on the physical stability of adenovirus type 5. J Pharm Sci (2006) 0.86
PROTS: a fragment based protein thermo-stability potential. Proteins (2011) 0.86
Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine. J Pharm Sci (2012) 0.86
Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies. J Pharm Sci (2012) 0.85
Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles. Eur J Pharm Sci (2003) 0.85
Comparative kinetics of cofactor association and dissociation for the human and trypanosomal S-adenosylhomocysteine hydrolases. 2. The role of helix 18 stability. Biochemistry (2008) 0.85
The inhibitory action of phospholamban involves stabilization of alpha-helices within the Ca-ATPase. Biochemistry (2002) 0.85
Probing protein structure and dynamics by second-derivative ultraviolet absorption analysis of cation-{pi} interactions. Protein Sci (2006) 0.85
A fluorescence study of the structure and accessibility of plasmid DNA condensed with cationic gene delivery vehicles. J Pharm Sci (2003) 0.85
Structure/function analysis of peptoid/lipitoid:DNA complexes. J Pharm Sci (2003) 0.84
The response of type three secretion system needle proteins MxiHDelta5, BsaLDelta5, and PrgIDelta5 to temperature and pH. Proteins (2008) 0.84
Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. J Pharm Sci (2013) 0.84
Preparation and characterization of taxane-containing liposomes. Methods Enzymol (2005) 0.84
High-throughput screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vaccin (2007) 0.84
Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci (2012) 0.84
Improving the stability of the EC1 domain of E-cadherin by thiol alkylation of the cysteine residue. Int J Pharm (2012) 0.84
A stopped-flow kinetic study of the assembly of nonviral gene delivery complexes. Biophys J (2005) 0.84
Stabilization of proteins by low molecular weight multi-ions. J Pharm Sci (2002) 0.84
Stability of helix-rich proteins at high concentrations. Biochemistry (2006) 0.84
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci (2012) 0.84
Hyaluronic acid nanoparticles titrate the viscoelastic properties of viscosupplements. Langmuir (2013) 0.84
Two-dimensional correlation spectroscopy reveals coupled immunoglobulin regions of differential flexibility that influence stability. Biochemistry (2007) 0.84